The US arm of drug firm Dr Reddy's Laboratories is recalling around 70,000 vials of Zoledronic acid injection manufactured by Gland Pharma from the US market, the latest report of the US health regulator has said.
Dr Reddy's Laboratories Inc is "recalling 59,468 vials of Zoledronic acid injection, 5mg/100 mL (0.05 mg/mL) 100ml vial," Enforcement Report of the United States Food and Drug Administration (USFDA) said.
The company is also recalling 10,530 vials of Zoledronic acid injection, 5 mg/100 mL (0.05 mg/mL) one 100ml single-dose bottle, it added.
The vials are being recalled on account of "Out-of-specification result observed for related substance: unknown impurity," the report said.
The product was distributed to retailers, distributors, physician officers and medical facilities throughout the United States, it added.
The vials were manufactured by Gland Pharma for Dr Reddy's Laboratories, the Enforcement Report said.
As per the USFDA "all recalls monitored by FDA are included in the Enforcement Report once they are classified and may be listed prior to classification when FDA determines the firm's removal or correction of a marketed product(s) meets the definition of a recall.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
